Chromocell Corporation

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company located in North Brunswick, New Jersey. The company employs 29 people and generates approximately $50 million in annual revenue. Chromocell develops and commercializes non-opioid, non-addictive therapeutics targeting the sodium ion channel NaV1.7 for the treatment of chronic and acute pain conditions. Their pipeline includes therapies designed to alleviate a range of issues, including mild to moderate pain, acute migraines, nausea and vomiting associated with chemotherapy, surgery, or anesthesia. Chromocell's portfolio also consists of innovative single-use spray devices intended to deliver these medications sublingually or intranasally. Chromocell's key differentiator is its focus on developing alternative pain management solutions free from the risks associated with traditional opioid medications. Their innovative platform technology aims to provide effective, safe, and convenient treatment options for patients seeking relief from pain and related ailments. For the latest company news, updates, or to learn more about Chromocell's initiatives, please visit www.chromocell.com.